SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024197
Filing Date
2022-11-10
Accepted
2022-11-10 08:36:11
Documents
81
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20220930.htm   iXBRL 10-Q 3454684
2 EX-10.1 cadl-ex10_1.htm EX-10.1 118964
3 EX-31.1 cadl-ex31_1.htm EX-31.1 19170
4 EX-31.2 cadl-ex31_2.htm EX-31.2 20001
5 EX-32.1 cadl-ex32_1.htm EX-32.1 11315
6 EX-32.2 cadl-ex32_2.htm EX-32.2 11877
  Complete submission text file 0000950170-22-024197.txt   10368343

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20220930_pre.xml EX-101.PRE 388379
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cadl-20220930_def.xml EX-101.DEF 261051
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20220930_lab.xml EX-101.LAB 501905
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20220930.xsd EX-101.SCH 65542
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cadl-20220930_cal.xml EX-101.CAL 42758
75 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20220930_htm.xml XML 1577872
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 221375139
SIC: 2836 Biological Products, (No Diagnostic Substances)